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Highlights 
• Rare structural variants contribute significantly to the genetic architecture of TS. 
• Increased global CNV burden is driven by large, rare, clinically relevant events. 
• NRXN1 deletions and CNTN6 duplications confer a substantial increase in TS risk. 
Summary 
Tourette syndrome (TS) is a model neuropsychiatric disorder thought to arise from abnormal development and/or 
maintenance of cortico-striato-thalamo-cortical circuits. TS is highly heritable, but its underlying genetic causes 
are still elusive, and no genome-wide significant loci have been discovered to date. We analyzed a European 
ancestry sample of 2,434 TS cases and 4,093 ancestry-matched controls for rare (< 1% frequency) copy-number 
variants (CNVs) using SNP microarray data. We observed an enrichment of global CNV burden that was 
prominent for large (> 1 Mb), singleton events (OR = 2.28, 95% CI [1.39–3.79], p = 1.2 × 10−3) and known, 
pathogenic CNVs (OR = 3.03 [1.85–5.07], p = 1.5 × 10−5). We also identified two individual, genome-wide 
significant loci, each conferring a substantial increase in TS risk (NRXN1 deletions, OR = 20.3, 95% CI [2.6–
156.2]; CNTN6 duplications, OR = 10.1, 95% CI [2.3–45.4]). Approximately 1% of TS cases carry one of these 
CNVs, indicating that rare structural variation contributes significantly to the genetic architecture of TS. 
Keywords 
Tourette Syndrome, tic disorders, neurodevelopmental disorders, genetics, structural variation, copy number 
variation, NRXN1, CNTN6 
Introduction 
Tourette syndrome (TS) is a complex neuropsychiatric disorder characterized by multiple 
chronic involuntary motor and vocal tics, with an estimated population prevalence of 0.3%–
0.9% (Scharf et al., 2015). Tics typically emerge during childhood and peak in adolescence, 
with a subsequent reduction in symptoms, supporting the notion that TS is 
neurodevelopmental in origin (Robertson et al., 2017). Most TS patients (> 85%) present with 
additional neuropsychiatric comorbidities, typically attention deficit hyperactivity disorder 
(ADHD) and obsessive-compulsive disorder (OCD) (Hirschtritt et al., 2015), although the risk 
for mood, anxiety, major depressive, and autism spectrum disorders (ASD) is also elevated 
(Burd et al., 2009, Hirschtritt et al., 2015). Consequently, TS is often considered a model 
neuropsychiatric disorder in that identification of its underlying molecular, cellular, and 
neurophysiologic etiology may be broadly applicable to a wide range of psychiatric disorders. 
Neuroimaging (Greene et al., 2016, Marsh et al., 2009) and neurophysiology (Draper et al., 
2014, Gilbert et al., 2004) studies suggest that TS and its associated comorbidities (e.g., OCD 
and ADHD) arise from dysregulated development and/or maintenance of parallel cortico-
striatal-thalamo-cortical (CSTC) motor, limbic, and cognitive circuits (Jahanshahi et al., 2015). 
Though non-genetic factors have been associated with increased TS risk (Browne et al., 2016, 
Leivonen et al., 2016), TS is primarily a genetic disorder. Family studies indicate that children 
of affected parents have a 60-fold higher risk of developing TS or chronic tics (CT), a closely 
related disorder, compared to the general population (Browne et al., 2015). TS heritability is 
estimated to be 0.77 (Mataix-Cols et al., 2015), making it one of the most heritable complex 
neuropsychiatric disorders. Despite this strong genetic component, the identification of bona 
fide TS susceptibility genes has proven challenging. Although linkage analyses have identified 
several candidate regions, there is little consensus across studies, suggesting that, as with 
other neuropsychiatric disorders, TS is genetically complex and heterogeneous (Robertson 
et al., 2017). Similarly, analyses of TS genetic architecture using aggregated SNP data 
demonstrate that TS is highly polygenic, with the majority of inherited TS risk distributed 
throughout the genome (Davis et al., 2013), though an initial genome-wide association study 
(GWAS) did not yield any genome-wide significant loci, likely due to small sample size (Scharf 
et al., 2013). 
Studies examining rare structural variation in individuals with TS have implicated several 
neurodevelopmental genes involved in neurite outgrowth and axonal migration. Rare 
chromosomal abnormalities affecting CNTNAP2 (Verkerk et al., 2003) and SLITRK1 (Abelson 
et al., 2005) have been found in isolated TS families, and exonic copy-number variants (CNVs) 
in NRXN1 are reported in small genome-wide studies (Nag et al., 2013, Sundaram et al., 
2010), though no locus has yet survived genome-wide correction for multiple testing. Because 
of evidence suggesting that rare CNVs may have a role in TS etiology (Fernandez et al., 2012, 
McGrath et al., 2014), and since such variants contribute to susceptibility for other heritable 
neurodevelopmental disorders (NDDs) (Malhotra and Sebat, 2012), we assessed the impact of 
rare CNVs on TS disease risk in a large sample of 6,527 unrelated individuals of European 
ancestry. We demonstrate a global increase in the burden of large, rare CNVs in TS cases 
compared to controls driven primarily by large, singleton events, in particular large (> 1Mb) 
deletions, consistent with marked genetic heterogeneity. We also report the first two TS 
susceptibility loci that meet genome-wide significance: deletions in NRXN1 and duplications in 
CNTN6. Each confers a substantial increase in disease risk and together are present in 1% of 
TS cases. 
Results 
An overview of the sample selection, quality control, CNV detection, and data analysis 
performed in this study is presented in Figure 1 and described in detail in the STAR Methods. 
All TS cases and controls were recruited through the Tourette Syndrome Association 
International Consortium for Genetics (TSAICG) or through the Gilles de la Tourette Syndrome 
GWAS Replication Initiative (GGRI), with additional controls selected from external studies 
(STAR Methods). All DNA samples were genotyped on the Illumina OmniExpress SNP array 
platform (Table S1A). We restricted analysis to SNP assays common to all array versions. We 
conducted extensive quality-control analyses including both SNP-based and CNV-based 
exclusion of outliers (Table S1B; STAR Methods) and genotype-based determination of 
ancestry (Figure S1). The final dataset consisted of 6,527 unrelated European ancestry 
samples: 2,434 individuals diagnosed with TS and 4,093 unselected controls. 
 
Figure 1. Flow Chart of Experimental Procedures and Analyses 
CNVs were called from genome-wide SNP genotype data generated from 2,434 TS cases and 4,093 
controls (gray). Data processing, CNV detection, and quality control steps (blue) are described in the 
STAR Methods. An outline of the main analyses is presented in red. Figures or tables relevant to each 
outlined step are shown in parentheses. 
Genome-wide detection of CNVs was performed using the consensus of two widely used 
Hidden Markov Model (HMM)-based methods (STAR Methods). Additionally, we used a locus-
specific, intensity-based clustering method to generate CNV genotypes in all samples across 
11 common HapMap3 loci for sensitivity analysis (Figure S2; Table S2; STAR Methods). Using 
the proportion of concordant HMM-based calls at these loci as a sensitivity measure, we 
confirmed the absence of any bias in CNV detection between cases and controls across all loci 
(p = 0.54, Fisher’s Exact test) and between individuals (p = 0.15, Welch’s t test; see Table S3). 
Post-call cleaning was performed and CNVs were annotated for gene content and frequency 
(STAR Methods). CNVs were considered “genic” if they overlapped any exon of a known 
protein-coding RefSeq transcript. Frequencies were defined based on a 50% overlap with 
other CNVs as described elsewhere (CNV and Schizophrenia Working Groups of the 
Psychiatric Genomics Consortium, 2017); “singletons” denote CNVs with a frequency of one 
across the entire dataset. We filtered calls for rare (frequency < 1% or < 65 events) CNVs ≥ 30 
kb in length and spanning at least ten probes. Finally, using a heuristically derived series of 
in silico validation metrics, we removed aberrant CNV calls due to mosaicism and misclassified 
rare events (Figure S3; STAR Methods). In total, we resolved 9,375 rare CNVs (Table S4). 
Global Burden Analysis of Rare CNVs in TS 
An increase in rare CNV burden has been consistently demonstrated in other NDDs (CNV and 
Schizophrenia Working Groups of the Psychiatric Genomics Consortium, 2017). Controlling for 
potential confounders, burden analysis was performed using logistic regression (STAR 
Methods) with three different burden metrics: (1) total number of CNVs (CNV count), (2) total 
genomic size of all CNVs (CNV length), and (3) number of genes affected (CNV gene count). 
For genic CNVs (n = 4,604), we observed modest but significant increases in burden across all 
metrics (Figure 2A): CNV count (OR 1.05 [1.01–1.10], p = 0.027), CNV gene count (OR 1.09 
[1.01–1.17], p = 0.019), and CNV length (OR 1.15 [1.07–1.24], p = 1.9 × 10−4). By contrast, no 
enrichment was seen in a comparable number (n = 4,771) of non-genic events. The increased 
burden in TS was most significant for CNV length and consistent across each control set 
individually (Figure S4). To explore the CNV length burden further, we partitioned the data 
across a range of CNV size and frequency bins and observed the enrichment was mainly 
attributable to large (> 1 Mb; OR 1.26 [1.08–1.49], p = 5.3 × 10−3) (Figure 2B) and/or singleton 
CNVs (OR 1.13 [1.04–1.24], p = 2.9 × 10−3) (Figure 2C). 
 
Figure 2. Rare CNV Burden in 2,434 TS Cases and 4,093 Controls 
(A) The global burden of all rare (< 1% frequency) CNVs > 30 kb is shown for genic (top) and non-genic 
(bottom) CNVs and stratified by CNV type (all, loss [deletions], gain [duplications]). Global CNV burden is 
compared using three different metrics: CNV count, total number of CNVs per subject; CNV length, 
aggregate length of all CNVs (in Mb); and CNV gene count, number of genes spanned by CNVs. Control 
rate, averaged baseline burden metric per control subject. Red boxes, odds ratios (box size is 
proportional to standard error); blue lines indicate 95% confidence intervals. Genic CNVs are defined as 
those that overlap any exon of a known protein-coding gene (see STAR Methods). 
(B) Analyses in (A) were assessed further by partitioning CNV length burden of all CNVs (deletions + 
duplications) into different CNV size categories. Whiskers represent 95% confidence intervals. 
(C) The analysis in (B) was repeated for CNVs binned by frequency. 
Odds ratios (OR) were calculated from logistic regression adjusted for covariates using standardized 
burden metrics (STAR Methods). ORs > 1 indicate an increased TS risk. 
Enrichment of Large, Singleton Events and Clinically Relevant CNVs 
We next explored whether specific CNV classes were enriched in TS. Since the elevated TS 
CNV burden was confined to large and/or very rare events, we re-evaluated the CNV count 
burden restricted to genic singletons, stratified by CNV size. We observed a significant 
enrichment of singletons > 500 kb (OR 1.43 [1.06–1.95], p = 0.020) that was further increased 
in the largest size category (> 1 Mb, OR 2.28 [1.39–3.79], p = 1.2 × 10−3). The enrichment of > 
1 Mb genic CNVs was greater for deletions (OR 2.75 [1.28–6.29], p = 0.012) than duplications 
(OR 1.98 [1.04–3.83], p = 0.038) (Figure 3A). Notably, the enrichment of singleton deletions > 
1 Mb was driven by CNVs spanning genes under strong evolutionary constraint (probability of 
loss-of-function intolerance [pLI] score > 0.9; Lek et al., 2016) (rate ratio = 2.65 [1.40–5.00], 
p = 2.7 × 10−3; Poisson regression; STAR Methods). 
 
Figure 3. Large, Singleton CNVs and Known Pathogenic Variants Are Overrepresented in TS 
(A) CNV count burden restricted to genic singleton events, stratified by CNV size and type 
(deletion/duplication). 
(B) CNV burden of all rare CNVs, classified by clinical relevance (benign, uncertain, pathogenic) 
according to the American College of Medical Genetics guidelines (STAR Methods). 
Red boxes, odds ratios; blue lines, 95% CIs. ORs > 1 represent an increase in risk for TS per CNV. 
It is well established that certain regions of the human genome are prone to rare, recurrent 
CNVs associated with a broad range of NDDs (Malhotra and Sebat, 2012). To evaluate if such 
pathogenic CNVs confer risk for TS, we classified all rare CNV calls by clinical relevance 
according to American College of Medical Genetics (ACMG) guidelines (Kearney et al., 2011) 
and assessed for enrichment between cases and controls. Known pathogenic CNVs were 
identified in 1.9% of TS cases versus 0.8% of controls (OR 3.03 [1.85–5.07], p = 1.5 × 10−5) 
(Figure 3B). Consistent with an increased pathogenicity of deletions compared to duplications, 
this enrichment was greater for deletions alone (OR per CNV 3.94 [1.83–8.95], p = 6.3 × 10−4). 
By contrast, no increase in burden was observed among CNVs classified as either benign or of 
unknown clinical significance. 
Deletions in NRXN1 and Duplications in CNTN6 Confer Substantial Risk for 
TS 
To test our sample for enrichment of rare CNVs at individual loci, we conducted an unbiased, 
point-wise (segmental) genome-wide association test, treating deletions and duplications 
independently (STAR Methods). As non-overlapping CNVs affecting the same gene would be 
unaccounted for by segmental assessments of enrichment, we also conducted a 
complementary gene-based test, conditioned on CNVs affecting exons. In contrast to SNP-
based GWAS, there is no established p value threshold to indicate genome-wide significance 
for CNVs, since the number of rare CNV breakpoints per genome varies across individuals and 
detection platforms. Therefore, for both tests, we established both locus-specific p values (Pseg 
and Pgene for segmental and gene-based tests, respectively) and genome-wide corrected p 
values (Pcorr) empirically through 1,000,000 label-swapping permutations, using the max(T) 
method (Westfall and Troendle, 2008; STAR Methods) to control for family-wise error rate 
(FWER). Both tests converged on the same two loci, one for deletions and another for 
duplications, which were enriched among TS cases and survived genome-wide correction for 
multiple testing. 
For deletions, the peak segmental association signal was located on chromosome 2p16 (Pseg = 
7.0 × 10−6; Pseg-corr = 1.0 × 10−3; Figure 4A), corresponding to heterozygous losses affecting the 
first coding exon of NRXN1, and found exclusively among TS cases (N = 10, Figure 4B). In the 
gene-based test of exonic CNVs, heterozygous NRXN1 deletions were also the most 
significant association genome-wide (Pgene = 5.9 × 10−5; Pgene-corr = 8.5 × 10−4), representing 12 
cases (0.49%) and 1 control (0.02%), corresponding to a substantially increased TS risk (OR 
20.3 [2.6–156.0]). Consistent with previously identified pathogenic NRXN1 deletions in other 
NDDs, these exon-spanning CNVs clustered at the 5′ end and predominantly affected the 
NRXN1-α isoform (Dabell et al., 2013). 
 
Figure 4. Segmental and Gene-Based Tests Converge on Two Distinct Loci Significantly 
Enriched in TS Cases 
(A) Manhattan plot of segmental association test results representing genome-wide corrected p values 
calculated at each CNV breakpoint. The two genome-wide significant association peaks correspond to 
deletions at NRXN1 (Pseg = 7.0 × 10−6, Pseg-corr = 1.0 × 10−3) and duplications at CNTN6 (Pseg = 5.4 × 10−5, 
Pseg-corr = 6.9 × 10−3). Red and blue levels correspond to a genome-wide corrected α of 0.01 and 0.05, 
respectively. 
(B) Heterozygous exonic deletions in NRXN1 found in 12 cases (0.49%) and 1 control (0.02%), 
corresponding to an OR = 20.3, 95% CI (2.6–156.0). Exon-affecting CNVs cluster at the 5′ end of NRXN1, 
with deletions affecting the first coding exon found in 10 cases and no controls (pink-shaded bar). Red, 
deletions in TS cases; dark red, deletion in controls; blue, case duplication. 
(C) Exon-spanning duplications over CNTN6 found in 12 cases and 2 controls (OR = 10.1 [2.3–45.4]). 
CNTN6 duplications are considerably larger in cases compared to controls (640 versus 143 kb, on 
average). Blue, case duplications; dark blue, control duplications; red, case deletion; dark red, control 
deletion. 
For duplications, the segmental association test identified one genome-wide significant locus 
on chromosome 3p26, within CNTN6 (Pseg = 5.4 × 10−5, Pseg-corr = 6.9 × 10−3), with a secondary 
peak located directly upstream (Pseg = 5.9 × 10−5, Pseg-corr = 6.9 × 10−3, Figures 4A and 4C). 
Closer inspection revealed an enrichment of large duplications spanning this gene. The gene-
based test identified the same locus, exonic CNTN6 duplications, with heterozygous gains 
found in 12 cases (0.49%) and 2 controls (0.05%), corresponding to an OR = 10.1 (2.3–45.4) 
(Pgene = 2.5 × 10−4, Pgene-corr = 8.3 × 10−3). Notably, the CNTN6 duplications in TS cases were 
considerably larger than those in controls (641 versus 143 kb). Eight of 12 TS carriers 
harbored a duplication > 500 kb in length, while duplications in controls were < 200 kb. 
All genic CNV calls across NRXN1 and CNTN6 were verified by inspection of probe-level 
intensity plots (Figures S5 and S6). No additional loci were significant after controlling for 
FWER, under either segmental or gene-based tests of association, and we obtained similar 
results after pair-matching each case with its closest ancestrally matched control, suggesting 
that these results are not due to inter-European population stratification (Figure S7; STAR 
Methods). 
Discussion 
In this study, we demonstrate a significant role for rare structural variation in the pathogenesis 
of TS, a still poorly understood neurodevelopmental disorder. We observe an increased global 
burden of rare CNVs and report two definitive TS risk loci that surpass empirical thresholds for 
genome-wide significance, deletions in NRXN1 and duplications in CNTN6. 
NRXN1 is a highly studied, pre-synaptic cell-adhesion molecule involved in synaptogenesis 
and synaptic transmission at both glutamatergic and GABAergic synapses (Pak et al., 2015). 
NRXN1 is primarily transcribed from two alternative promoters, resulting in a full-length 
NRXN1-α isoform and a shorter C-terminal NRXN1-β isoform (Ushkaryov et al., 1992). 
NRXN1-α contains six alternative splice sites, which in combination generate hundreds of 
unique transcripts that segregate within specific brain regions and cell types (Fuccillo et al., 
2015, Schreiner et al., 2014). NRXN1-α isoforms preferentially bind to various trans-synaptic 
partners, including neuroligins, cerebellins, neurexophilins, and leucine-rich repeat 
transmembrane proteins, each of which subserves different synaptic functions (de Wit and 
Ghosh, 2016). NRXN1-α trans-synaptic interactions play a critical role in thalamo-cortical 
synaptogenesis and plasticity (Singh et al., 2016), suggesting one possible mechanism in 
support of the prevailing theory that TS arises from abnormal sensorimotor CSTC circuit 
development (Jahanshahi et al., 2015). 
Although previous studies have observed heterozygous exonic NRXN1 deletions in TS cases 
(Fernandez et al., 2012, Nag et al., 2013, Sundaram et al., 2010), small sample sizes 
precluded a definitive association of this gene with TS. We demonstrate, in a large 
independent sample, that exonic NRXN1 deletions confer a substantial increase in TS risk. 
The association of heterozygous NRXN1 deletions with different NDDs is one of the most 
reliable findings in the neuropsychiatry CNV literature (Dabell et al., 2013). Consistent with 
this, 4 of the 12 TS cases with exonic NRXN1 deletions in our sample had another broadly 
defined NDD (2 ASD, 1 developmental delay, 1 developmental speech/language disorder 
unspecified) (Table S5), supporting the hypothesis that these deletions may interfere with a 
generalized neurodevelopmental process that, when combined with other disease-specific 
mutations and/or background polygenic risk, results in the observed phenotypic pleiotropy. 
Like NRXN1, CNTN6 encodes a cell-adhesion molecule expressed primarily in the CNS 
(Ogawa et al., 1996). Contactins are members of the L1 immunoglobulin superfamily of 
proteins, and Cntn6 serves multiple functions in the developing mouse nervous system, 
including orientation of apical dendrites in cortical pyramidal neurons, regulation of Purkinje 
cell development and synaptogenesis, and oligodendrocyte differentiation from 
neuroprogenitor cells (Oguro-Ando et al., 2017). Mice with homozygous inactivation of Cntn6 
also exhibit reproducible motor impairment (Huang et al., 2012). 
Duplications in CNTN6 represent a novel association for TS. CNVs affecting CNTN6 have 
been reported in isolated cases of intellectual disability/developmental delay (ID/DD) 
(Kashevarova et al., 2014), and deletions alone are enriched in ASD (Mercati et al., 2016). 
Notably, in a clinical series of 3,724 patients referred for cytogenetic testing, all seven CNTN6 
duplication carriers either presented with or had a first-degree relative with ADHD and/or OCD, 
while none of the seven CNTN6 deletion carriers were diagnosed with these two common TS 
comorbidities (Hu et al., 2015). In our study, the rates of co-morbid OCD/ADHD were not 
increased in TS CNTN6 CNV carriers compared to non-carriers, and no TS CNTN6 carrier was 
noted to have ASD/ID/DD (Table S5). 
Several limitations of the current study can inform future inquiry. First, although our sample 
represents the largest survey of CNVs in TS to date, it is still underpowered to detect 
extremely rare CNVs and/or those of moderate effect. While we show strong evidence for the 
involvement of deletions across NRXN1, our data also do not support other similarly implicated 
loci, including deletions in COL8A1 (Nag et al., 2013), which we observed in a single TS 
patient. This emphasizes the need for larger, independent samples for continued discovery 
and refinement of candidate TS loci. Second, while our TS cases were well characterized for 
OCD and ADHD, we did not formally assess ASD, ID, schizophrenia, or epilepsy. Parents 
and/or adult subjects were queried about existing diagnoses of these NDDs as well as learning 
disorders/developmental delay, but cases with milder ASD/DD may not have been detected. 
Additional efforts should focus on characterizing the full scope of phenotypes associated with 
NRXN1 and CNTN6 CNVs. A comprehensive molecular analysis of these CNVs is also 
needed to fully understand how they increase risk for such phenotype(s). Finally, the elevated 
burden observed here is largely confined to large singletons and known pathogenic CNVs, 
consistent with a global enrichment of CNVs under strong negative selection that possibly 
arose de novo or within the last few generations. This suggests that, in addition to substantial 
increases in sample size, alternative study designs that allow for discrimination of de novo 
CNVs will be fruitful for TS, as was recently shown for likely-gene-disrupting variants identified 
by exome sequencing in TS trios (Willsey et al., 2017). 
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Contact for Reagent and Resource Sharing 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Jeremiah M. Scharf (jscharf@partners.org). 
Experimental Model and Subject Details 
Sample Ascertainment 
Tourette Syndrome (TS) cases (n = 2,243) were ascertained primarily from TS specialty clinics 
through sites distributed throughout North America, Europe and Israel as part of an ongoing 
collaborative effort by the Tourette Syndrome Association International Consortium for 
Genetics (TSAICG; https://www.findtsgene.org/) as described previously (Scharf et al., 2013). 
Subjects were assessed for a lifetime diagnosis of TS, Obsessive Compulsive Disorder (OCD) 
and Attention-Deficit/Hyperactivity Disorder (ADHD) using a standardized and validated semi-
structured direct interview (TICS Inventory) (Darrow et al., 2015). TS case samples were also 
obtained through web-based recruitment of individuals with a prior clinical diagnosis of TS who 
subsequently completed an online questionnaire that has been validated against the gold-
standard TS structured diagnostic interview with nearly 100% concordance for all 
inclusion/exclusion criteria as well as high correct classification rates for DSM-IV diagnoses of 
OCD and ADHD (Darrow et al., 2015). Individuals for web-based screening were solicited 
through the Tourette Association of America mailing list as well as from 4 TS specialty clinics 
in the United States. Individuals with a history of intellectual disability, seizure disorder, or a 
known tic disorder unrelated to TS were excluded. 
Additional cases (n = 628) and ancestry-matched controls (n = 544) were collected by the 
Gilles de la Tourette Syndrome Genome-wide Association Study Replication Initiative (GGRI) 
through 9 TS specialty clinics in Austria, Canada, France, Germany, Greece, Hungary, Italy 
and the Netherlands by expert clinicians using Tourette Syndrome Study Group criteria for 
Definite TS (DSM-IV TS diagnosis plus tics observed by a trained clinician) as well as DSM-IV 
diagnostic criteria for OCD and ADHD as described previously (Paschou et al., 2014). We did 
not conduct formal standardized assessments for other neurodevelopmental disorders (NDDs) 
such as Intellectual Disability/Developmental Delay (ID/DD), Autism Spectrum Disorder (ASD), 
or schizophrenia/childhood psychosis; however, participants and their parents were asked 
about the presence of established or suspected diagnoses. 
74.3% of TS cases were male, consistent with the 3- to 4-fold higher prevalence of the 
disorder in males compared to females (Robertson et al., 2017). The median age of cases was 
17 (IQR, 12-31). 
All participants provided written informed consent (parental consent and written assent were 
obtained for individuals under 18). This study was approved by the institutional review boards 
of all participating sites. 
Method Details 
External Control Sets 
Additional control subjects were taken from four external large-scale genetic studies consisting 
of individuals sampled from similar geographic locations, specifically selected because 
intensity data were available and generated on the same Illumina OmniExpress platform as the 
TS cases and controls collected as part of this study: 
1. Cardiff Controls (CC) (Green et al., 2010): UK Blood donors were recruited in Cardiff at the 
time of blood donation at centers in Wales and England. Although not explicitly screened for 
psychiatric disorders, these controls are likely to have low rates of severe neuropsychiatric 
illness, as blood donors in the UK are only eligible to donate if they are not taking any 
medications. 
2. Consortium for Neuropsychiatric Phenomics (CNP) (Bilder et al., 2009): A collection of 
neuropsychiatric samples composed of patients with ADHD, bipolar disorder (BD), 
schizophrenia (SCZ), and psychologically normal controls, collected throughout North America 
as part of a large NIH Roadmap interdisciplinary research consortia centered at the University of 
California, Los Angeles (UCLA). 
3. Genomic Psychiatry Cohort (GPC) (Pato et al., 2013): A large, longitudinal, population 
resource composed of clinically ascertained patients affected with BD, SCZ, their unaffected 
family members, and a large set of control samples with no family history of either disorder. 
Samples were collected at various sites throughout North America in a National Institute of 
Mental Health-sponsored study lead by the University of Southern California. 
4. Wellcome Trust Case Control Consortium 2 (WTCCC2) (Power and Elliott, 2006): A subset of 
control samples from the National Blood Donors Cohort. 
Genotyping 
Samples selected for this study were all genotyped on the Illumina OmniExpress Exome v1.1 
(Illumina, San Diego, CA, USA) in three separate batches (TS1-3), while samples from the CC, 
CNP, GPC, and WTCCC2 sets were genotyped on the Illumina OmniExpress 12v1.0 (Illumina, 
San Diego, CA, USA). A summary of the datasets, genotyping centers, and arrays used is 
provided in Table S1A. The OmniExpress Exome and OmniExpress arrays are identical except 
for the presence of exome-focused content on the former and additional intensity-only markers 
on the latter. We have observed that exome-specific assays in general exhibit a much higher 
variance overall in their Log-R Ratios (LRR) values. Therefore, in order to avoid detection 
biases due to this differential variance and to unequal probe density, only the SNP assays with 
common identifiers for all array versions across all datasets were used for quality control (QC) 
and CNV detection, a total of 689,077 markers. 
To ensure the generation of the most reliable SNP calls, intensity measures, and B-allele 
frequencies (BAF), a custom cluster file was generated for each dataset separately and for 
each genotype batch when such information was available. Since the performance of 
Illumina’s proprietary normalization and cluster generation process improves with the number 
of samples, we processed all of the raw intensity data available, regardless of clinical 
phenotype. An initial round of QC was carried out using Beeline v1.0 (Illumina, San Diego, CA, 
USA) to determine baseline call rates and LRR standard deviation (LRR_SD) for each sample 
using the canonical cluster file (∗.egt) provided by the manufacturer for each array version. Any 
sample with a call rate < 0.98 or an LRR_SD > 0.30 was deemed a failed assay and removed 
(Pre-cluster QC, Table S1B). SNP clustering and genotype calling was then performed with 
only the passing samples for each dataset individually with GenomeStudio v2.0 (Illumina, San 
Diego, CA, USA). 
Genotype Sample QC 
We performed an initial round of QC based on SNP genotype data. All samples at this stage 
had a minimal call rate > 0.98. Samples with with discordant sex status were excluded. For 
samples run in duplicate, we retained the assay with the higher call rate. We filtered autosomal 
SNPs for missingness, minor-allele frequency, and deviation from Hardy-Weinberg equilibrium 
before pruning SNPs for LD using the following options in PLINK v1.9 (Chang et al., 2015): 
A total of 96,350 SNPs remained for Identity-By-State relatedness testing. For all pairs of 
subjects (and duplicate/repeated samples) with PI_HAT > 0.185, we removed the sample with 
the lower call rate, with the exception that if a control individual was related to a subject with a 
neuropsychiatric phenotype, it was explicitly removed. Additionally, we excluded 44 subjects 
that were identical (PI_HAT > 0.99) between the CNP and GPC cohorts. 
Ancestry Estimation 
Following the exclusion of all clinical non-TS samples from external studies, genotype data for 
the remaining samples was combined with data from publicly available continental HapMap 
samples of CEU, YRI, and CHB/JPT ancestry genotyped on the OmniExpress array (Illumina, 
San Diego, CA, USA). Available European (EU) samples from the 1000 Genomes Project 
(http://www.internationalgenome.org/) genotyped on the Omni platform were also included to 
establish an appropriate calibration threshold for EU ancestry designation. We thinned our 
dataset randomly to 19,024 LD-independent markers for ancestry inference using fastStructure 
(Raj et al., 2014) with k = 3. Samples were excluded if they contained > 0.0985 non-EU 
ancestry (Figure S1). A final round of ancestry exclusion was performed by removing all 
samples outside of the median ± 3SD on the first three ancestry principal components (PCs). 
CNV Calling 
We created GC wave-adjusted LRR intensity files for all samples using PennCNV’s 
genomic_wave.pl script, and employed two widely used HMM-based CNV calling algorithms, 
PennCNV v2011-05-03 (Wang et al., 2007), and QuantiSNP v2.0 (Colella et al., 2007) to 
initially detect structural variants in our dataset. For PennCNV, we generated a custom 
population B-allele frequency file for each dataset separately before calling CNVs using 
emission probabilities defined in the file hhall.hmm. QuantiSNP calls were generated from the 
GC-adjusted intensity files using the configuration file levels-hd.dat. A Perl script was used to 
merge concordant calls generated by both algorithms. CNVs were merged by taking the 
intersection of overlapping calls of the same CNV type (deletion or duplication). Additionally, 
adjacent CNV calls were merged if they were spanned by a CNV called by the other HMM 
algorithm. As HMMs have been shown to artificially break up large CNVs, we also merged 
CNV segments in the final concordant callset if they were of the same copy number and the 
number of intervening markers between them was less than 20% of the total of both segments 
combined using the PennCNV’s clean_cnv.pl script. We repeated this joining process 
iteratively until no more merging of segments occurred. Scripts and utility files used to 
generate CNV calls are available on bitbucket (https://bitbucket.org/ucla_coppolalab/tscnv). 
Intensity Sample QC 
The PennCNV calling algorithm generates a number of array intensity-based metrics with 
regard to CNV assay quality. Intensity-based QC was conducted based on the distribution of 
all available assays and subsequently combined with the results from the SNP-based QC. To 
remove samples with data unsuited for CNV detection, we used empirically defined thresholds 
across several different metrics: 
1. Waviness factor (WF) - measures the waviness in intensity values, a known artifact caused 
by improper DNA concentration that can lead to spurious calls. 
2. Log-R ratio standard deviation (LRR_SD) - a measure of the overall variance in intensity. 
3. B-allele frequency drift (BAF_DRIFT) - summary of the deviation of BAF from expected 
values. 
Thresholds for WF and LRR_SD were determined separately for each dataset by both manual 
examination of QC metrics and/or taking the mean +3x SD to determine outlying samples. 
Following intensity-based QC, all samples had an LRR-SD of < 0.24, absolute value of WF < 
0.04, and an BAF_DRIFT < 0.001, well within established limits required for reliable CNV 
detection. 
CNV-load Sample QC 
Although SNP and intensity-based QC removed most failed assays, we performed a final 
round of sample QC, removing eight additional samples with excessively high CNV load based 
on the total number of CNV calls (> 45) or total CNV length (> 10Mb). These thresholds were 
determined empirically by visual inspection of distributions across all datasets combined. Our 
final dataset after QC consisted 6,527 samples: 2,434 TS cases and 4,093 controls. 
Data Handling and CNV Visualization 
To facilitate further data processing and visualization of CNV events, we generated an HDF5 
database consisting of sample metadata, CNV calls, probe information, LRR intensity and BAF 
values for all assays. Normalized intensity values were also generated by converting the GC-
corrected, median-centered LRR measures into Z-scores within each sample and inserted into 
the database. Visualization of cluster plots (Figures S2A, S2B, S3C); median Z-score outlier 
detection (MeZOD) CNV calls (Vacic et al., 2011) (Figure 3B); and probe-level CNV plots 
(Figures S5 and S6) were generated from Z-scores of intensity data using in Matplotlib. Python 
code to create the HDF5 database and perform associated plotting functions is available on 
bitbucket (https://bitbucket.org/ucla_coppolalab/tscnv). 
Sensitivity Assessment 
We augmented a previously described method (Vacic et al., 2011) to investigate whether any 
difference in sensitivity to detect CNVs existed between cases and controls within the context 
of our study. Both HMM-based CNV callers we employed for genome-wide detection are 
univariate methods completely agnostic of intensity information across multiple samples and 
do not use known population frequency prior probabilities in their calling algorithms. Therefore, 
common CNVs act as an ideal proxy to evaluate the effectiveness to detect rare events 
accurately; they are detected in the same manner but are present at much higher frequencies, 
enabling an accurate estimation of the overall sensitivity of detection for rare events genome-
wide. 
We used the UCSC Genome Browser (https://genome.ucsc.edu) liftOver tool to translate a list 
of common HapMap3 CNVs to the hg19 reference. To match the thresholds used for our 
association tests in this study, we filtered the list of common CNVs to those that were > 30 kbp 
in length. We reduced the number of markers required slightly to a minimum of 9 to ensure that 
an adequate number of events could be assessed. For each common CNV meeting these 
criteria, we examined the distribution of median-summarized normalized intensity measures 
within the CNV region across all study samples and retained only those loci that displayed no 
evidence of clustering intro different copy-number states. A total of 11 common CNV loci were 
retained for sensitivity analysis (Figure S2). 
We generated locus-specific genotyping calls in the following manner. First, we extracted the 
LRR intensity Z-scores for all probes in the region across all samples. The Z-scores for all 
probes spanning the CNV locus were then subjected to second round of normalization across 
all samples. A Gaussian mixture model (GMM) was fit to this distribution of Z-scores using the 
SciKit-learn Python package. The optimum number of clusters was automatically determined 
by minimization of the Bayesian Information Criterion (BIC) and corrected, when necessary, by 
manual adjustment. Individuals were assigned to a cluster only if the posterior probability of 
assignment exceeded 0.95. Python code to perform GMM-based genotyping at specific loci is 
available on bitbucket (https://bitbucket.org/ucla_coppolalab/tscnv). 
Copy number state was inferred by examining the original LRR intensity values for samples 
within each cluster. We inspected for allele frequency differences between controls and cases 
for all clusters and found no significant difference (Fisher's exact test, Table S2). We collapsed 
the clusters at each locus into CNVs of the same type (deletion or duplication). As this locus-
specific genotyping method is more sensitive than HMM segmentation methods, we used the 
proportion of concordant of HMM-based calls as a proxy for genome-wide detection sensitivity. 
We found no significant difference in sensitivity to detect common CNVs between phenotypic 
groups at any of the 11 loci tested, either independently, or in concert (Fisher’s exact test, 
Table S3A and S3B). Furthermore, the mean sensitivity for each sample was calculated and 
collectively assessed for any systematic difference between phenotypic groups. Considering 
duplications, deletions, or both in concert, we observed no significant difference in the 
sensitivity of segmentation calls between case and control groups (Welch’s t test, Table S3C). 
Call Filtering and Delineation of Rare CNVs 
Calls were removed from the dataset if they spanned less than 10 markers, were less than 
30kb in length, or overlapped by more than 0.5 of their total length with regions known to 
generate artifacts in SNP-based detection of CNVs. This included immunoglobulin domain 
regions, segmental duplications, and regions that have previously demonstrated associations 
specific to Epstein-Barr virus immortalized cell lines (Shirley et al., 2012). In addition, we 
removed calls that spanned telomeric (defined as 100kb from the chromosome ends), 
centromeric regions, and gaps in the reference genome. As described elsewhere (CNV and 
Schizophrenia Working Groups of the Psychiatric Genomics Consortium, 2017), we assigned 
all CNV calls a specific frequency count using PLINK v.1.07 (Purcell et al., 2007), with the 
option --cnv-freq-method2 0.5. Here, the frequency count of an individual CNV is determined 
as 1 + the total number of CNVs overlap by at least 50% of its total length (in bp), irrespective 
of CNV type. We then filtered our callset for CNVs with MAF < 1% (a frequency of 65 or lower 
across 6,527 samples). Furthermore, we removed calls if they shared more than a 50% 
reciprocal overlap in length to common CNVs regions derived from several large, publically 
available SNP-array datasets, compiled by the Database of Genomic Variation and Phenotype 
in Humans using Ensembl Resources (DECIPHER; https://decipher.sanger.ac.uk/index): 
1. 845 population samples from the Deciphering Developmental Disorders study. 
2. 450 population samples from the 42M genotyped study. 
3. 5919 population samples from the Affy6 study. 
Conservatively, CNV regions were only considered common if present at a frequency of > 10% 
within any individual dataset above. Exclusion intervals and code to perform regional filtering of 
CNVs is available on bitbucket (https://bitbucket.org/ucla_coppolalab/tscnv). 
In Silico Validation 
For each putative rare CNV, we generated two different metrics based on LRR intensity and 
BAF banding. To qualify CNVs based on intensity, we adopted a scoring methodology similar 
to the MeZOD method described elsewhere (Kirov et al., 2012), with modification. We 
observed that standardized intensity measures typically range from < −20 for homozygous 
deletions, [-6,-2.3] for heterozygous deletions, and > 1.3 for duplications. Because of the 
disproportionately large effect on intensity measures caused by homozygous deletions events 
in Illumina data, performing a second round of normalization across all samples within each 
putative CNV will skew the overall distribution when these events are present. Therefore, we 
only performed a single round of normalization of LRR intensity measures, within each sample. 
Each CNV was scored by calculating the median of LRR intensity Z-scores (LRR-Z) for all 
probes within the region. To qualify CNVs based on BAF banding, we calculated the proportion 
of probes within the CNV region that showed evidence of a duplication event (BAF of [0.25-04] 
or [0.6-0.8]), and denoted this measure “BAF-D.” 
Based on thresholds established through manual inspection of large CNVs, we flagged 
deletions that had a LRR-Z > −2 or BAF-D > 0.02, and duplications with a LRR-Z < 1 or BAF-
D < 0.1. To avoid differential missingness caused by subtle differences between datasets, we 
did not impose any hard cutoff for CNV exclusion based on these metrics. These thresholds 
were applied to flag CNV calls with marginal scores for manual inspection for the exclusion of 
obviously misclassified events. Through this in silico validation process we discovered multiple 
instances of large CNV calls likely due to individual mosaicism (Figure S3A and S3B), and 
removed these events from subsequent analysis. 
Furthermore, for each rare CNV call, we used distribution of summarized intensity information 
across all individuals. For each rare CNV region, we quantified proportion of samples whose 
LRR-Z metric fell outside of [-2.3, 1.3] and further inspected these regions manually. Putative 
rare CNV loci that showed substantial evidence for extensive polymorphism were 
subsequently scored for frequency using the GMM genotyping method described above 
(Figure S3C) and conservatively, only removed if shown to be variant in more than 10% of the 
samples across the entire dataset. Python code to generate in silico metrics for CNV calls from 
intensity data stored in an HDF5 database is available on bitbucket 
(https://bitbucket.org/ucla_coppolalab/tscnv). 
Annotation of Rare CNVs 
Rare CNVs were annotated for gene content according to RefSeq provided by the hg19 
assembly of the UCSC Genome Browser. We only considered a CNV as “genic” if it 
overlapped any exon of a known protein-coding transcript (as designated by the RefSeq 
transcript accession prefix “NM”). The “gene count” of a CNV represents the total number of 
non-redundant genes whose respective transcripts it overlaps. “Non-genic CNVs” represent all 
variants that are not genic according to the definition above. 
In addition, all rare CNVs were assessed for clinical relevance in accordance with guidelines 
set forth by the American College of Medical Genetics (ACMG) (Kearney et al., 2011). This 
was accomplished through the use of the Scripps Genome Advisor (SGA) 
(https://genomics.scripps.edu/ADVISER/); inspection of curated resources including ClinVar 
(https://www.ncbi.nlm.nih.gov/clinvar/), DECIPHER (https://decipher.sanger.ac.uk/index), and 
Online Mendelian Inheritance in Man (https://www.omim.org/); and followed by confirmation 
through review of primary literature. Conservatively, we only considered a CNV as 
“pathogenic” if directly supported by more than one primary publication. To screen for 
additional relevant pathogenic variants, we included variants that overlapped compiled lists 
defined in the literature (Malhotra and Sebat, 2012, McGrath et al., 2014). All non-pathogenic 
variants were automatically annotated by SGA: those classed as Category 2-4 were assigned 
as a variant of “unknown clinical significance,” and those assigned to Category 5 were 
considered “benign.” Note that, as only rare CNVs were considered, the number of “benign” 
variants is small. 
Rare genic CNVs were further annotated using pLI (probability of LoF Intolerance) scores 
(http://exac.broadinstitute.org/). A CNV was marked as “constrained” if it overlapped any exon 
of a gene with a pLI score of > 0.9, as per the approach by Ruderfer and colleagues (Ruderfer 
et al., 2016). 
Global CNV Burden Analysis 
We measured global CNV burden using three separate metrics: the number of rare CNVs 
(CNV count), the total length of all CNVs (CNV length) and the total number of genes 
intersected by CNVs (CNV gene count). To examine the effect of different covariates on 
different metrics of global CNV burden, we first fit a linear regression model for each burden 
metric, using the glm function in R: 
Burden_metric ∼ subject_sex + ancestry_PCs + LRR_SD 
In the above model, ancestry_PCs included the first ten PCs derived from SNP data and, as 
various assay intensity quality metrics are highly correlated, LRR_SD was used as a single 
measure of assay quality. Across the entire dataset, only PC2 and LRR_SD were associated 
(p < 0.05) with global CNV burden as measured by CNV count. To assess for a global burden 
difference between TS cases and controls, we fit the following general logistic regression 
model: 
𝑇𝑇𝑇𝑇_𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 ∼ 𝐵𝐵𝑠𝑠𝐵𝐵𝐵𝐵𝐵𝐵𝐵𝐵_𝑚𝑚𝐵𝐵𝑠𝑠𝐵𝐵𝑚𝑚𝑚𝑚 + 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝐵𝐵𝑚𝑚𝑠𝑠_𝑠𝑠𝐵𝐵𝑠𝑠 + 𝑃𝑃𝑃𝑃1 + 𝑃𝑃𝑃𝑃2 + 𝑃𝑃𝑃𝑃3 + 𝑃𝑃𝑃𝑃4+ 𝐿𝐿𝐿𝐿𝐿𝐿_𝑇𝑇𝑆𝑆 
Independent variables included burden metric, subject sex, and the first 4 ancestry PCs. Even 
though assay quality (LRR_SD) was associated exclusively with small CNV burden (< 
100kbp), it was included in all burden analysis, regardless of size. For all burden analyses, 
ORs, 95% CIs, and significance were calculated using the R function glm (family = ”binomial”). 
ORs were calculated by taking the exponential of the logistic regression coefficient. 
To examine whether evolutionarily constrained CNVs are enriched in TS patients, we assumed 
a Poisson distribution of such rare events, and conducted a Poisson regression using the R 
function glm (family = ”poisson”) with the same covariates as in the logistic regression above, 
including adjustment of subject sex, the first four ancestry PCs, and LRR_SD: 
Constrained_CNVs
∼ TS_status + subject_sex + PC1 + PC2 + PC3 + PC4+ LRR_SD 
We tested large (> 1Mb), singleton CNVs that affect conserved genes (pLI > 0.9), stratified by 
CNV type, and compared the relative risk of such events to all large, singleton genic CNVs. 
In Figure 2, global burden was analyzed separately for genic CNVs and non-genic CNVs. 
Since we were interested in comparing the relative contribution to TS risk by different 
measures of burden and across various categories, sizes, and frequency classes, the ORs 
presented in Figure 2 and Figure S4 are calculated from standardized CNV burden metrics. 
For Figure 3 and elsewhere, we calculated ORs using the unstandardized value of actual CNV 
counts, as this is directly interpretable. R code to perform burden analysis is available on 
bitbucket (https://bitbucket.org/ucla_coppolalab/tscnv). 
Locus-specific Tests of Association 
The segmental test of association was performed by quantifying the frequencies of case and 
control CNV carriers at all unique CNV breakpoint locations; the unique set of CNV 
breakpoints defines all locations genome-wide where the frequency of CNVs can differ 
between cases and controls. For gene-based association tests, we restricted our analysis to 
genic CNVs (CNVs that intersect an exon of any protein-coding transcript, as defined above) 
and quantified the frequencies of cases and control CNVs across each gene. Locus-specific p 
values for both tests of association were determined by 1,000,000 permutations of phenotype 
labels, and genome-wide corrected p values were obtained using the max(T) permutation 
method (Westfall and Troendle, 2008) as implemented in PLINK v1.07, which controls for 
family-wise error rate by comparing the locus-specific test statistic to all test statistics genome-
wide within each permutation. Association tests were conducted separately for deletions and 
duplications. 
Sensitivity Analysis of Association Results 
The segmental association test was repeated after carefully pair-matching each case with a 
control such that the global difference between each pair was minimized using GemTools (Lee 
et al., 2010) (Figure S7). For the matched segmental association analysis, because of the 
drastic reduction in sample size, a genome-wide corrected alpha < 0.05 was used as a cutoff 
to indicate significance. 
Quantification and Statistical Analysis 
All statistical analyses were performed using R v3.4.0 or PLINK v1.07. R code and example 
commands to perform all statistical analyses are available on bitbucket 
(https://bitbucket.org/ucla_coppolalab/tscnv). For sensitivity assessment (see “Sensitivity 
Assessment”), as also indicated in the main text and/or Tables S2 and S3, we used a Fisher's 
exact test to test for a difference between cases and controls in: the frequency of non-
reference genotypes at common CNV loci (Table S2), the sensitivity of HMM-based CNV calls 
at these loci individually (Table S3A), and the sensitivity of HMM-based CNV across all loci 
(Table S3B). For Table S3C, we used Welch’s t test to test if the average sensitivity per 
individual differed between cases and controls, assuming that the variance of this measure 
was not necessarily equal between groups. For common CNVs, we did not expect allele 
frequency or detection sensitivity to differ between cases and controls and therefore, 
significance was assessed using a two-sided test. 
To allow for the inclusion of covariates, we used a logistic regression framework to evaluate 
the contribution of global CNV burden on TS risk. ORs above 1 indicate an increased risk for 
TS per unit of CNV burden, 95% CIs are provided for all estimates (see “Global Analysis of 
CNV Burden”). For Figure 2 and S4, global burden was measured by CNV count, CNV length, 
or CNV gene count as indicated, and by CNV count for Figure 3 and elsewhere. Burden 
measures were aggregated per individual, genome-wide, and restricted to specific CNV 
categories as described. To test whether evolutionarily constrained CNVs are enriched in TS 
patients, we assumed a Poisson distribution of such rare events, and compared the rates of 
constrained CNVs between TS cases and controls using Poisson regression. 
For association testing, we performed 1 × 106 label-swapping permutations to determine both 
locus-specific and genome-wide p values empirically using the max(T) method (Westfall and 
Troendle, 2008) as implemented in PLINK v1.07. This method is appropriate given all samples 
were processed through the same CNV calling pipeline on identical assays. For the segmental 
test, case and control frequencies were calculated at each unique CNV breakpoint. For the 
gene-based test, frequencies were based on the number of genic CNVs at each gene locus. 
Deletions and duplications were tested independently, using a 1-sided test as we expect an 
increased frequency of CNVs in cases compared to controls. 
Data and Software Availability 
Data 
CNV calls for all samples are provided in Table S4. Intensity files for the TSAICG datasets are 
available at dbGaP: phs001380.v1.p (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs001380.v1.p1). 
Software 
Utility files and custom code written in BASH, Perl, Python, and R used to conduct this analysis 
and generate figures from this manuscript are available on bitbucket 
(https://bitbucket.org/ucla_coppolalab/tscnv). 
Additional Resources 
TSAICG website: https://www.findtsgene.org 
Bitbucket repository: https://bitbucket.org/ucla_coppolalab/tscnv 
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